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Abstract
Background: AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and
activated in numerous human carcinomas and sarcomas, including aggressive subtypes of liposarcoma. However,
the role of AXL in the pathogenesis of well-differentiated (WDLPS), dedifferentiated (DDLPS), and pleomorphic
liposarcoma (PLS) has not yet been determined.
Methods: Immunohistochemical analysis of AXL expression was conducted on two tissue microarrays containing
patient WDLPS, DDLPS, and PLS samples. A panel of DDLPS and PLS cell lines were interrogated via western blot
for AXL expression and activity and by ELISA for growth arrest-specific 6 (GAS6) production. AXL knockdown was
achieved by siRNA or shRNA. The effects of AXL knockdown on cell proliferation, migration, and invasion were
measured in vitro. In addition, AXL shRNA-containing DDLPS cells were assessed for their tumor-forming capacity
in vivo.
Results: In this study, we determined that AXL is expressed in a subset of WDLPS, DDLPS, and PLS patient tumor
samples. In addition, AXL and its ligand GAS6 are expressed in a panel of DDLPS and PLS cell lines. We show that
the in vitro activation of AXL via stimulation with exogenous GAS6 resulted in a significant increase in cell
proliferation, migration, and invasion in DDLPS and PLS cell lines. Transient knockdown of AXL resulted in
attenuation of these protumorigenic phenotypes in vitro. Stable AXL knockdown not only decreased migratory and
invasive characteristics of DDLPS and PLS cells in vitro but also significantly diminished tumorigenicity of two
dedifferentiated liposarcoma xenograft models in vivo.
Conclusions: Our results suggest that AXL signaling contributes to the aggressiveness of DDLPS and PLS, and that
AXL is therefore a potential therapeutic target for treatment of these rare, yet devastating tumors.
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Background
Soft tissue sarcomas include over 50 histologically dis-
tinct subtypes of mesenchymal malignancies and ac-
count for approximately 1 % of all adult solid cancers in
the United States [1]. Liposarcomas (LPS) are one of the
most common subtypes of soft tissue sarcoma, compris-
ing nearly 20 % of cases. The World Health
Organization recognizes four distinct histological sub-
types of LPS: atypical lipomatous tumor (ALT)/well dif-
ferentiated LPS (WDLPS), dedifferentiated LPS
(DDLPS), myxoid LPS, and pleomorphic LPS (PLS); the
tumors in these groups differ in morphology, genetic
composition, and clinical behavior [2].
Approximately 40–45 % of LPS are ALT/WDLPS,
which are locally aggressive and rarely metastatic. These
tumors are characterized by amplification of the 12q13-
15 chromosomal region, which ultimately results in the
formation of supernumerary rings and/or giant rod
chromosomes [3]. In this study, we will use the term
WDLPS instead of ALT/WDLPS. WDLPS tumors have a
propensity for local recurrence as well as dedifferenti-
ation with subsequent metastasis [2]. A dedifferentiated
cellular component within WDLPS occurs in approxi-
mately 10 % of cases, and these biphasic tumors are clas-
sified as DDLPS [2]. Like WDLPS, DDLPS occurs most
frequently in the retroperitoneum and to a lesser extent
in the extremities. Nearly all DDLPS cases (90 %) are
identified within the primary tumor, while the remainder
of incidences may appear in the context of a WDLPS re-
currence [2]. DDLPS are typically considered to be
intermediate-to-high-grade malignancies, with a local re-
currence rate of approximately 60 % and a metastatic
rate of 15–20 %, resulting in 5-year survival rates of ap-
proximately 30–55 % [2, 4]. PLS, which accounts for
only 5 % of LPS diagnoses, is more aggressive, exhibits
complex karyotypes, and tends to develop in deep soft
tissues of the extremities, with rare instances of retro-
peritoneal occurrence [2]. The aggressiveness of PLS is
highlighted by a 30–50 % metastatic rate, a five-year sur-
vival rate of 25–60 %, and an overall survival rate of 40–
50 % [2, 5, 6]. Currently, there is a lack of effective che-
motherapeutic or targeted therapies for WDLPS,
DDLPS, and PLS, with surgical resection remaining the
primary standard of care for patients with these sarco-
mas [7]. Biological insights are needed to identify mo-
lecular mechanisms that may be clinically useful as
potential therapeutic targets in LPS.
We recently showed that AXL was highly upregulated
in LPS cells versus normal preadipocytes and adipocytes
[8]. AXL is a member of the TYRO3-AXL-MER (TAM)
family of receptor tyrosine kinases (RTKs). Activation of
AXL via its ligand GAS6 (growth arrest-specific 6)
stimulation promotes cellular processes such as survival,
proliferation, migration, and cell-cell adhesion, while
inhibiting apoptosis [9–13]. In addition, overexpression
of AXL has been implicated in the development and
progression of numerous malignancies; furthermore,
AXL has been identified as a predictor of poor patient
outcome in lung, breast, and pancreatic cancer, renal cell
carcinoma, and glioblastoma [9, 14–23]. High levels of
activated AXL have been linked to increased chemore-
sistance in lung and breast cancers, esophageal carcin-
oma, and acute myeloid leukemia [24–27].
It has also been reported that RNAi-mediated knock-
down of AXL in pancreatic adenocarcinoma and breast
and lung cancer cells decreases migration, invasion,
tumor growth, and metastasis and also impairs angio-
genesis [18, 19, 28–31]. Taken together, those previous
studies suggest that AXL may be a key signaling node
regulating several biological processes during tumorigen-
esis and cancer progression. However, the role of AXL
in the pathogenesis of LPS has not been determined.
Our study aimed to investigate the role of AXL in
WDLPS, DDLPS, and PLS through the analysis of pa-
tient samples, cell lines, and xenograft models.
Methods
Clinically annotated tissue microarray
This study was approved by The University of Texas
MD Anderson Cancer Center (UTMDACC) institutional
review board and informed consent was obtained from
all patients. By using the UTMDACC prospective sar-
coma database, institutional tumor registry, and path-
ology archives, 46 WDLPS and 19 DDLPS formalin-
fixed paraffin-embedded samples from 45 patients who
presented to UTMDACC from January 2000 to February
2009 and subsequently underwent surgical resection
were selected for tissue microarray (TMA) inclusion.
The TMA was constructed as previously described, with
two 0.6-mm punches per sample embedded into a TMA
block [32]. Hematoxylin-eosin verification was per-
formed on 4 μm sections. An additional TMA composed
of 39 PLS patient samples from 32 patients that was pre-
viously constructed by our research group was also used
to examine AXL expression [33]. Normal fat (NF; n =
12) specimens were included as a control.
Cell lines
Human DDLPS cell lines Lipo-224A, Lipo-224B, Lipo-
246, and Lipo-863, the DDLPS cell strain Lipo-573, and
the PLS cell line PLS-1 were derived and cultured in our
laboratory as previously described [8]. Lipo-573 was sub-
sequently removed from our panel due to observed senes-
cence. The PLS cell lines LS2 and LiSa2 were maintained
as previously described [34]. The DDLPS cell line LPS141
was kindly provided by Dr. Jonathan Fletcher (Dana-Far-
ber Cancer Institute, Boston, MA) [35]. Primary human
white preadipocytes were purchased from PromoCell
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(Heidelberg, Germany) and maintained in commercially
available preadipocyte growth medium (PromoCell). Hu-
man white preadipocytes were differentiated into adipo-
cytes in culture with a commercially available
preadipocyte differentiation medium according to the
manufacturer’s instructions (PromoCell). Both preadipo-
cytes and adipocytes were used as experimental controls.
DDLPS and PLS cells were grown in Dulbecco modified
Eagle medium (DMEM) supplemented with 10 % fetal bo-
vine serum (FBS), 100 U/mL penicillin, and 100 μg/mL
streptomycin. Established cell lines were validated via
short tandem repeat DNA fingerprinting as previously de-
scribed [36].
Antibodies and reagents
Commercially available antibodies were purchased for
immunoblotting or immunohistochemical detection of
AXL. pAXL Y702, AKT, pAKT S473, ERK, and pERK
T202/T204 (Cell Signaling Technology, Danvers, MA);
MER (GeneTex, Irvine, CA); TYRO3 (Abcam, Cam-
bridge, MA); Ki67 and cleaved caspase 3 (Biocare Med-
ical, Concord, CA); and β-actin–horseradish peroxidase
(Santa Cruz Biotechnology, Dallas, TX). Recombinant
human GAS6 was purchased from R&D Systems (Min-
neapolis, MN).
Western blot analysis
Standard protocols for western blot analyses of whole
cell extracts were followed [8]. For GAS6 stimulation ex-
periments, cells were serum-starved in 1%FBS-DMEM
overnight and then stimulated for 30 min with 400 ng/
mL recombinant GAS6, a concentration previously de-
scribed to activate AXL in vitro [11, 20, 21].
Quantification of GAS6 via Enzyme-Linked Immunosorb-
ent Assay (ELISA)
Antibody sandwich ELISAs (R&D Systems, Minneapolis,
MN) were used to measure secreted GAS6 in human
primary preadipocytes, adipocytes, and DDLPS and PLS
cell lines in low-serum conditions (1 % FBS; 24 h). Sam-
ples of conditioned DMEM (1 % FBS) were obtained
from preadipocytes, adipocytes, and cell lines after 24 h,
after which the total number of cells was calculated. Se-
creted GAS6 levels were normalized to cell number.
Assessment of cell proliferation
Cell proliferation was evaluated using a CellTiter 96
AQueous One Solution Cell Proliferation Assay (con-
taining 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;
MTS) (Promega, Madison, WI) according to the manu-
facturer’s instructions. Briefly, cells were seeded in 96-
well plates at a density of 1.5 × 103 cells/well in 100 μL
of medium and assayed for proliferation after 48 h. For
experiments with GAS6, 24 h after seeding, the medium
was replaced with low-serum medium (1 % FBS) with or
without 400 ng/mL recombinant GAS6. Cell prolifera-
tion was assayed 48 h later (72 h total). For experiments
with small interfering RNA (siRNA), cells were seeded
48 h post-transfection and proliferation was measured
48 h thereafter (96 h after transfection). Following the
addition of MTS reagent, plates were incubated for 2 h
at 37 °C, and absorbance was read at 490 nm. For each
experiment, proliferation was assayed in triplicate, and
the percent cell proliferation was normalized to the
control.
Modified Boyden chamber assays
Migration and invasion assays were performed using cell
culture inserts with 8 μm polyethylene terephthalate
(PET) filters with or without Matrigel (Becton Dickinson
Labware, Franklin Lakes, NJ). Briefly, 2.5 × 104 cells
were seeded in the inserts of modified Boyden chambers
in low-serum (1 % FBS) DMEM/F12 medium. DMEM/
F12 medium containing 5 % FBS was used as a chemo-
attractant for these studies. Triplicate wells were used
for each experiment. For studies evaluating the effect of
GAS6-mediated AXL activation on migration and inva-
sion, 100 ng/mL GAS6 was added within the inserts at
the time of cell seeding. For experiments with siRNA,
cells were seeded 48 h post-transfection. After 14 h in-
cubation at 37 °C, cells were fixed with 10 % glutaralde-
hyde and stained with 0.2 % crystal violet in 20 %
methanol (Baxter Healthcare, Houston, TX). Migratory
and invasive cells were quantified using ImageJ version
1.47 software (http://rsbweb.nih.gov/ij/index.html) [37].
Transient and stable knockdown of AXL
For transient knockdown of AXL, 20 nM pools of ON-
TARGETplus human AXL-targeting siRNA or a 20 nM
pool of control nontargeting (NT) constructs (Dharma-
con, Lafayette, CO) were introduced into cells using X-
tremeGene (Roche, Indianapolis, IN) per the manufac-
turer’s instructions. Cells were transfected at 45–50 %
confluency in six-well plates and seeded for MTS, migra-
tion, and invasion assays 48 h after transfection. Knock-
downs were evaluated via western blot analyses of whole
cell extracts harvested 72 h after transfection.
Stable knockdown of AXL was achieved by transfect-
ing cell lines with the short hairpin RNA (shRNA)
pGIPZ lentiviral constructs containing anti-AXL or NT
sequences (Open Biosystems, Lafayette, CO; AXL
shRNA #1, V3LHS_329651; AXL shRNA #2,
V3LHS_329652; NT sequence, RHS4346). Lentiviruses
were generated at the MD Anderson shRNA and
ORFeome Core. Target cells were infected with lenti-
virus, followed by selection with 1 μg/mL puromycin.
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AXL knockdown was confirmed via western blot
analyses.
In vivo experiments
All animal procedures were approved by the UTM-
DACC Institutional Animal Care and Use Committee.
Animals received humane care in accordance with the
Animal Welfare Act and the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals. To evaluate the effect of AXL knockdown on
tumorigenicity, suspensions of Lipo-246 or Lipo-863
cells (2.5 × 106 or 3.5 × 106 cells/0.1 mL of phosphate
buffered saline (PBS) per mouse, respectively) expressing
either AXL-specific or NT shRNA lentiviral constructs
were subcutaneously injected into the flanks of 6-week-
old female hairless severe combined immunodeficiency
(SCID) mice (n = 8 per construct) (Charles River Labora-
tory, Wilmington, MA). Tumor size was measured bi-
weekly. When control tumors reached a volume of
1500 mm3, all mice were sacrificed and their tumors
resected, weighed, and frozen or fixed in formalin.
Formalin-fixed tissues were subsequently embedded in
paraffin for IHC analyses.
Immunohistochemistry
For TMA and xenograft analyses, AXL immunostaining
was independently scored by two observers (E.G.D. and
A.J.L.). Tumor cores missing from the TMA sectioned
slides were omitted from analyses. Staining was classified
as either negative (intensity of stain scored as 0 or 1) or
positive (intensity of stain scored as 2 or 3). Xenograft-
derived specimens were further analyzed for Ki67 (cell
proliferation marker) and cleaved caspase 3 (CC3; apop-
tosis marker) expression.
Statistical analysis
In vitro assays were repeated at least three times; the
mean and standard error of the mean (SEM) were calcu-
lated for each assay. Two-tailed Student t-tests were
used to assess significance. Means and SEMs were also
calculated for xenograft studies. Differences in xenograft
volumes and weights between AXL-specific and NT
Fig. 1 AXL and its ligand, GAS6, are highly expressed in DDLPS and PLS. a AXL expression was assessed by IHC analysis of TMAs containing NF
samples and WDLPS, DDLPS, and PLS tumor samples (representative images are shown, 200× magnification). b Western blot analyses of TAM
RTKs in panels of DDLPS and PLS cell lines. c GAS6 secretion was measured by ELISA in conditioned media for the indicated DDLPS and PLS cell
lines. The data are means with SEMs for triplicate experiments (* = p < 0.05)
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constructs were assessed using a two-tailed Student t-
test (* = p < 0.05 or *** = p < 0.001).
Results
AXL and its ligand GAS6 are highly expressed in a subset
of DDLPS and PLS
We first assessed AXL expression in human tumors by
conducting IHC analyses on two TMAs containing sam-
ples from WDLPS, DDLPS, and PLS patients. AXL ex-
pression was observed in 27.7 % (27/104 samples; 23/83
[27.7 %] of patients) of all evaluable LPS samples, with
no staining in NF specimens (Fig. 1a). AXL was detected
in 14/39 (35.9 %) of PLS samples, 4/19 (21.1 %) of
DDLPS samples, and 7/46 (15.2 %) of WDLPS samples
(Table 1). The vast majority of WDLPS and DDLPS
tumor samples were obtained from tumors in the retro-
peritoneum, while most PLS samples represented tu-
mors that originated in the extremities. We found that
all of the AXL-positive WDLPS and DDLPS samples
were obtained from retroperitoneal lesions. In addition,
all positive PLS samples were acquired from tumors lo-
cated in the extremities.
For the in vitro assessment of AXL expression and
function, we utilized several previously established
DDLPS and PLS cell strains and cell lines; however,
WDLPS cell strains do not grow in culture and there-
fore could not be experimentally tested. Similar to
our IHC analysis, immunoblotting of whole cell
lysates from DDLPS and PLS cell lines demonstrated
that four out of 6 DDLPS cell lines and cell strains
and all three PLS cell lines expressed higher levels of
both total AXL and its activated form (pAXL Y702)
compared with preadipocyte and adipocyte controls
(Fig. 1b). In comparison, other TAM family members
were not consistently overexpressed, with comparable
MER expression levels detected in the control and
test cell lines and variable TYRO3 expression in
DDLPS and PLS cells.
Next we assessed the levels of the AXL ligand
GAS6 in tumor cell-conditioned media in order to
determine the potential for autocrine activation of
AXL in LPS oncogenicity. We found significantly ele-
vated levels of secreted GAS6 in six out of the seven
DDLPS and PLS cell lines when compared to adipo-
cyte control cells, indicating that autocrine stimula-
tion by GAS6 may play a role in AXL activation
(Fig. 1c).
GAS6-mediated AXL activation promotes cell
proliferation, migration, and invasion of DDLPS and
PLS cells
In order to determine the enhancing effects of GAS6-
mediated signaling on the activation of AXL and its
downstream effectors in DDLPS and PLS, two DDLPS
cell lines (Lipo-246 and Lipo-863) and two PLS cell
lines (LiSa2 and PLS-1) were cultured in low-serum





Positive for AXL immunostain
Patients (%) (n = 83) Samples (%) (n = 104)
NF 12 12 0 (0) 0 (0)
LPS (Total) 83 104 23 (27.7) 27 (26.0)
LPS subtype
WDLPS
Extremity 3 3 - -
Retroperitoneum 31 43 7 (22.6) 7 (16.3)
Total 34 46 7 (20.6) 7 (15.2)
DDLPS
Extremity 1 1 - -
Retroperitoneum 17 18 4 (23.5) 4 (22.2)
Total 18 19 4 (22.2) 4 (21.1)
PLS
Extremity 23 29 10 (43.5) 11 (37.9)
Retroperitoneum 2 2 - -
Other a,b 7 8 2 (28.6) 3 (37.5)
Total 31 39 12 (37.5) 14 (35.9)
aOne patient with PLS had a primary tumor in the extremity as well as a metastatic lesion in the lung which was included on the TMA. Therefore, the total
number of PLS patients is 31, not 32
bOther locations include lung (n = 4 patients, 5 samples) and chest/back (n = 3 patients, 3 samples)
cSeveral patients had multiple tumor samples included on the TMA
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conditions overnight, followed by acute exposure to
GAS6. Serum starvation did not completely abrogate
AXL activation in Lipo-246, Lipo-863, and PLS-1,
suggesting that cell line-secreted GAS6 may allow for
a baseline level of AXL activation. Exogenous GAS6
stimulation increased AXL activation in all cell lines
evaluated; furthermore, Lipo-246, PLS-1, and LiSa2
cells displayed increased phosphatidylinositol-3-kinase
(PI3K) pathway activity, as measured by AKT phos-
phorylation at S473 (Fig. 2a). In most cell lines tested,
a minimal increase in the mitogen-activated protein
kinase (MAPK) pathway activity was noted, as deter-
mined by extracellular signal-regulated kinase (ERK)
phosphorylation at T202/Y204. Moreover, the addition
of exogenous GAS6 to DDLPS and PLS cells cultured
in low-serum media resulted in a moderate, yet sig-
nificant increase in cell proliferation, cell migration,
and invasion (Fig. 2b and c). Taken together, these re-
sults indicate that the GAS6/AXL signaling axis en-
hances protumorigenic phenotypes of DDLPS and
PLS cells in vitro.
Knockdown of AXL decreases protumorigenic properties
in vitro
After determining that AXL activation confers prolifera-
tive, migratory, and invasive properties to DDLPS and
PLS cells in vitro, we wanted to assess whether transient
knockdown of AXL could abrogate these processes.
Using an anti-AXL siRNA pool, we knocked down AXL
in DDLPS and PLS cells; a control pool of four NT con-
structs was used in parallel. As expected, AXL knock-
down resulted in reduced total AXL protein expression
and decreased AXL activation (Fig. 3a). We observed a
concomitant decrease in AKT activation, suggesting a re-
duction in PI3K signaling in all cell lines except PLS-1.
ERK activity was not strongly affected in any of the cell
lines evaluated. Moreover, attenuation of the AXL sig-
naling axis decreased cell proliferation in all cell lines
evaluated (Fig. 3b) and markedly reduced the migratory
and invasive capabilities of siAXL DDLPS and PLS cells
(Fig. 3c).
Next, we stably knocked down AXL to analyze the
long-term effects of decreased AXL expression on
Fig. 2 GAS6-mediated AXL activation increases protumorigenic properties of LPS cells in vitro. a DDLPS (Lipo-246 and Lipo-863) or PLS (LiSa2 and
PLS-1) cells were incubated with low-serum media for 24 h prior to a 15 min stimulation with 400 ng/mL GAS6 and analyzed via western blotting.
b Changes in DDLPS and PLS cell proliferation were measured by MTS assays with or without GAS6 stimulation for 48 h. Percent of cell growth is
expressed as a percentage of control. c Modified Boyden chambers were used to assess the effects of GAS6 stimulation on cell migration and
invasion. Representative images of each condition are shown (200× magnification). Percent of cell migration and invasion is expressed as a
percentage of control. The data in the bar graphs are means with SEMs for triplicate experiments (* = p < 0.05; *** = p < 0.001)
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tumorigenic phenotypes in vitro. DDLPS and PLS cells
were transduced either with one of two different AXL-
specific shRNA-containing lentiviruses (hereafter re-
ferred to as shRNA #1 or #2) or with the NT control
construct. Following selection and expansion, western
blots were used to examine the degree of stable AXL
knockdown in all four cell lines (Fig. 4a). Interestingly,
shRNA #1 reduced both AKT and ERK activities in
Lipo-246 and Lipo-863 cells, whereas shRNA #2 had the
opposite effect. AKT phosphorylation decreased with
both AXL-targeting shRNA constructs in the LiSa2 and
PLS-1 cell lines; however, ERK activity varied in the PLS
cell lines. With the exception of LiSa2 cells, cell prolifer-
ation was unaffected in vitro by stable AXL knockdown
(Fig. 4b). In contrast, AXL knockdown significantly re-
duced the migratory and invasive capacities in all four
cell lines with the exception of Lipo-246 cells transduced
with AXL shRNA #2; these cells had a significant in-
crease in migration (Fig. 4c). Although the phenotypic
responses of the individual cell lines to AXL knockdown
varied, migration and invasion were compromised in
most cell lines, an effect that may decrease tumorigen-
icity in vivo.
Stable AXL knockdown diminishes DDLPS tumor growth
in vivo
To evaluate growth of AXL shRNA-transduced DDLPS
cells in vivo, we subcutaneously injected Lipo-246 or
Lipo-863 cells with or without AXL knockdown (Figs. 5a
and 6a) into the flanks of female hairless SCID mice.
AXL knockdown in Lipo-246 and Lipo-863 cells signifi-
cantly reduced tumor volume (p < 0.001) compared with
that for NT control xenografts (Figs. 5b and 6b, respect-
ively). Additionally, a significant decrease in ex vivo
tumor weight (p < 0.05) was observed with AXL knock-
down in Lipo-246 xenografts; the weight of Lipo-863 tu-
mors with AXL knockdown were decreased compared
to the NT control although statistical significance was
not achieved (NT v shAXL #1: p = 0.055; NT v shAXL
#2: p = 0.052) (Figs. 5c and 6c). IHC analysis verified
Fig. 3 Transient knockdown of AXL decreases cell proliferation, migration, and invasion. a Representative western blots showing signaling
dysregulation in Lipo-246, Lipo-863, LiSa2, and PLS-1 cells that were transfected with either NT or AXL-specific siRNA. b Cell proliferation of
AXL-specific siRNA-transfected DDLPS and PLS cell lines was measured by MTS assay after 48 h (96 h post-transfection). Percent of cell growth is
expressed as a percentage of control. c Modified Boyden chambers were used to assess DDLPS and PLS cell migration and invasion following
transfection with AXL-targeting siRNA. Percent of cell migration and invasion is expressed as a percentage of control. The data in the bar graphs
are means with SEMs for triplicate experiments (* = p < 0.05; *** = p < 0.001)
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Fig. 4 Stable knockdown of AXL in DDLPS and PLS cells reduces cell proliferation, migration, and invasion. a Representative western blots
showing signaling alterations induced with stable knockdown of AXL in DDLPS and PLS cell lines. b MTS assays were performed on DDLPS and
PLS cell lines to evaluate cell proliferation after 48 and 96 h in AXL knockdown cells. Percent of cell growth is expressed as a percentage of
control. c After stable knockdown of AXL, the ability of DDLPS and PLS cell lines to migrate and invade was evaluated. Percent of cell migration
and invasion is expressed as a percentage of control. The data in the bar graphs are means with SEMs for triplicate experiments
(* = p < 0.05; *** = p < 0.001)
Fig. 5 Stable AXL knockdown in Lipo-246 cells significantly reduces tumor weight and volume. a AXL knockdown in Lipo-246 cells was evaluated
by western blot prior to subcutaneous injection. b Tumor volume was monitored at the indicated time points. c Xenografts were weighed ex vivo
following experiment termination. d Representative IHC images of Lipo-246 xenografts expressing NT control constructs or one of two
AXL-targeting shRNAs are shown (400× magnification). Hematoxylin-eosin (H&E); cleaved caspase 3 (CC3). (* = p < 0.05; *** = p < 0.001)
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decreased AXL expression in shRNA-transduced xeno-
grafts (Figs. 5d and 6d). Lower levels of Ki67 expression
by IHC confirmed decreased proliferation in both Lipo-
246 and Lipo-863 xenografts containing shRNA against
AXL compared with NT control xenografts. Lipo-246
AXL knockdown xenografts displayed elevated CC3,
suggesting an induction of apoptosis in these tumors.
Discussion
In this study, we have confirmed that AXL is overex-
pressed and activated in DDLPS and PLS cell lines and
corresponds to enhanced oncogenic signaling through
downstream PI3K/AKT and MAPK pathways, which fa-
cilitate certain tumorigenic processes such as prolifera-
tion, migration, and invasion. While the mechanism of
AXL overexpression is outside the scope of this study,
we found that DDLPS and PLS cells are capable of pro-
ducing and secreting GAS6 in an autocrine manner, and
that exogenous administration of GAS6 enhances activa-
tion of AXL and downstream effectors in these cells.
Taken together, these findings support an autocrine
mechanism of AXL activation via GAS6 secretion in
liposarcoma disease progression. Our observations sup-
port previous reports that the role of AXL in cancer is a
consequence of receptor overexpression and/or its in-
appropriate activation [38–40].
AXL signaling is involved in many cellular processes,
including survival, migration, invasion, and metastasis in
both normal and cancer cells [9–12]. We observed an
increase in proliferation, migration, and invasion in our
cell line model systems after stimulation with exogenous
GAS6, suggesting that activated AXL is an important
mediator of these processes in LPS. Most LPS cell lines
tested have high endogenous levels of activated AXL in
normal growth conditions in vitro; furthermore, Lipo-
246, Lipo-863, and PLS-1 had detectable pAXL expres-
sion in low serum, which suggests that stimulation via
LPS cell-secreted GAS6 may allow for a baseline level of
AXL activity and the promotion of proliferation, migra-
tion, and invasion. Consequently, increases in these pro-
cesses after the addition of exogenous GAS6 may be
tempered and therefore the observed results are modest
but significant.
Initially, we observed that AXL signaling following
stimulation with exogenous GAS6 is potentiated primar-
ily through the PI3K/AKT pathway in all cell lines
tested, as measured by an increase in pAKT, while a
mild increase in signaling through the MAPK pathway
was observed in 3 out of 4 cell lines. However, siRNA or
shRNA-mediated AXL knockdown did not have a uni-
form effect on either downstream pathway evaluated.
For instance, knockdown of AXL by siRNA resulted in a
slight decrease in PI3K/AKT signaling in two cell lines
(Lipo-246 and LiSa2), while both pAKT and pERK were
elevated in PLS-1. We noted that the effect on down-
stream pathways were variable following stable AXL
knockdown. It should also be noted that Lipo-863 had
consistently low or absent basal levels of pAKT and
therefore could not be included when assessing pathway
preferences for AXL. These data indicate that AXL sig-
naling can be propagated through both the PI3K/AKT
and MAPK pathways without any apparent preference,
Fig. 6 AXL knockdown in Lipo-863 reduces in vivo tumorigenicity. a Prior to subcutaneous injection, Lipo-863 cells were assessed for AXL by
immunoblotting. b Xenograft volume was measured three times weekly. c Tumors were harvested and weighed at the end of the experiment.
d Representative IHC images of Lipo-863 xenografts expressing NT control constructs or AXL-specific shRNAs are presented (400× magnification).
Hematoxylin-eosin (H&E); cleaved caspase 3 (CC3). (* = p < 0.05)
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and therefore merits further investigations into alterna-
tive downstream pathways.
Our findings for DDLPS and PLS cell lines were simi-
lar to those of previous studies in which transient AXL
knockdown with siRNA was associated with decreased
cell proliferation and a concomitant reduction in migra-
tion and invasion [19, 29–31]. Notably, long-term
shRNA-mediated knockdown of AXL did not signifi-
cantly reduce cell proliferation in vitro, which may be
due to activation of other pro-tumorigenic RTKs up-
stream of PI3K or MAPK signaling. We observed that
Lipo-246 cells expressing AXL shRNA (specifically,
shRNA #2) had high levels of pAKT, supporting the po-
tential for alternative means of pro-LPS pathway activa-
tion. Irrespective of downstream signaling, shRNA-
mediated AXL knockdown significantly diminished the
tumor-forming capacities of Lipo-246 and Lipo-863 cells
in vivo, a finding that indicates that AXL may represent
a molecular target in a subset of DDLPS tumors. Be-
cause reactivation of key canonical downstream path-
ways was observed in stable AXL knockdown cells in
vitro, the possibility exists that tumors may evade AXL
blockade in vivo, which could potentially result in ac-
quired resistance to AXL-targeted therapeutics.
The effect of AXL knockdown on in vivo tumorigenic
potential is cell line-dependent and may vary with the
degree of knockdown. Knockdown of AXL in Lipo-246
cells increased apoptosis and decreased cell proliferation,
greatly reducing tumor volume and weight. Lipo-863
shRNA-containing xenografts resulted in decreased cell
proliferation, but had minimal effect on apoptosis. These
results likely reflect alternate growth factor signaling
mediators that are active in different tumors. Knock-
down via shRNA #2 did not completely eliminate AXL
expression in Lipo-863; however, a significant reduction
in tumor volume and weight was noted. These results
indicate that moderate knockdown of AXL may be suffi-
cient to reduce tumorigenicity. Additionally in vivo stud-
ies interrogating the use of a pharmacological inhibitor
against AXL in vivo could further validate our findings
and shed more light onto the role of the receptor in dis-
ease progression.
Several small-molecule inhibitors of AXL are being
investigated as both single agents and in combination
for their anti-tumor effects in cancers with high AXL
expression [24–27, 41–45]. However, many are multi-
target inhibitors known to block signaling through
other RTKs such as c-MET, c-KIT, and SRC; there-
fore, the effects of these inhibitors cannot be fully as-
cribed to disrupted AXL activity [44, 45]. The AXL-
specific inhibitor, R428, has been shown to inhibit cell
growth and migration of erlotinib-resistant head and
neck cancer cells as well as to resensitize these cells
to erlotinib [41]. In our study, we observed examples
of potential adaptive resistance in the form of in-
creased PI3K/AKT signaling after shRNA-mediated
AXL knockdown in DDLPS cell lines and xenografts,
which may render cells insensitive to diminished AXL
activity over time. While we have yet to investigate
the effects of a small molecule inhibitor in our sys-
tem, the potential for resistance to reduced AXL ex-
pression and activity could indicate the need for
combination therapy. Use of both targeted therapy di-
rected at AXL and the PI3K pathway may yield su-
perior anti-LPS effects and improve patient outcome.
AXL has been identified as a predictor of poor prog-
nosis for several types of malignancies, including breast
cancer, pancreatic cancer, lung adenocarcinoma, osteo-
sarcoma, oral squamous cell carcinoma, and acute mye-
loid leukemia [18, 19, 21, 22, 46–48]. To determine
whether overexpression of AXL in cultured DDLPS and
PLS cell lines is an accurate representation of the human
disease, we performed IHC analyses of two TMAs by
comparing WDLPS, DDLPS, and PLS patient tumor
samples to NF controls. We observed higher levels of
AXL expression in DDLPS and PLS patient samples than
in NF samples or the lower-grade WDLPS samples. In
addition, we focused on the location of all tumors in-
cluded in the analysis as retroperitoneal WDLPS and
DDLPS generally denote a poorer patient prognosis [2].
Interestingly, AXL expression was detected solely in
WDLPS and DDLPS that were located in the retroperi-
toneum. Furthermore, PLS are inherently aggressive tu-
mors regardless of location, and nearly one third of PLS
samples were AXL positive. As we did not have compar-
able numbers of cases in each location, we were unable
to make any comparisons between retroperitoneal and
extremity WDLPS, DDLPS, and PLS. Additional studies
could further validate these findings. However, our re-
sults, when combined with previous findings, indicate
that AXL may contribute to tumor aggressiveness in
DDLPS and PLS and that further studies are warranted
to determine the utility of AXL as a potential molecular
prognosticator for LPS.
Conclusion
Overall, our data suggests that AXL is a potential thera-
peutic target in DDLPS and PLS; further investigations
into the effects of AXL-specific targeted therapies for
the treatment of LPS are warranted.
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